Vimizim approved in Japan for Morquio A Syndrome-BioMarin Pharma
The Japanese Ministry of Health, Labor and Welfare has granted approval of the registration of Vimizim (elosulfase alfa), from BioMarin Pharmaceutical, for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A Syndrome. Vimizim is the first treatment in Japan approved for this condition. Vimizim was reviewed under the Orphan Drug program. The FDA approved the Vimizim license application for the treatment of patients with Morquio A Syndrome on February 14, 2014. The therapy is also approved in Australia, Canada, Brazil and the European Union. Marketing applications have been submitted in several other countries.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins